Introduction {#H1-1-ZOI180067}
============

Chemotherapy lowers the risk of recurrence in early-stage cancers and can improve survival and symptoms in later-stage disease. Balancing these benefits against chemotherapy's considerable risks is challenging. Increasing evidence suggests that chemotherapy is too often started too late in the cancer disease trajectory,^[@zoi180067r1],[@zoi180067r2],[@zoi180067r3],[@zoi180067r4]^ and many patients die soon after initiating treatment. These patients experience burdensome symptoms without many of the potential benefits of chemotherapy.^[@zoi180067r5]^ National organizations now track the proportion of patients who die within 2 weeks of receiving chemotherapy as a marker of poor quality of care,^[@zoi180067r6],[@zoi180067r7]^ and this number has been increasing rapidly.^[@zoi180067r1],[@zoi180067r8]^

A key factor underlying these trends is the difficulty of accurately identifying the risk of serious adverse events, especially death, before initiating chemotherapy. Adverse effects of chemotherapy are variable, and the influence of comorbidities is complex; thus, the risk calculus of administering chemotherapy is challenging.^[@zoi180067r9],[@zoi180067r10],[@zoi180067r11],[@zoi180067r12],[@zoi180067r13]^ Cognitive biases also lead to underestimation of the risk of death,^[@zoi180067r14],[@zoi180067r15]^ particularly in patients with metastatic cancer,^[@zoi180067r16],[@zoi180067r17]^ who often believe that their disease is curable.^[@zoi180067r18],[@zoi180067r19]^ Physicians do not accurately estimate prognosis in patients with cancer,^[@zoi180067r20],[@zoi180067r21]^ and overly optimistic estimates can influence patients' chemotherapy decisions.^[@zoi180067r22],[@zoi180067r23],[@zoi180067r24],[@zoi180067r25],[@zoi180067r26],[@zoi180067r27]^

To estimate mortality before initiation of chemotherapy, physicians may reference randomized clinical trial (RCT) data for individual regimens or population-level data such as the Surveillance, Epidemiology, and End Results (SEER) data set to obtain mortality risk by age, sex, and primary cancer.^[@zoi180067r14],[@zoi180067r28]^ Although informative, these tools provide mortality estimates for broad populations of patients and often do not accurately estimate a specific individual's mortality. Individualized decision support tools exist^[@zoi180067r29]^ but require a substantial investment of time and resources; these tools require clinicians to collect and enter data not readily available in existing records, which limits the number of variables that can be used and adds complexity to workflows.

There is considerable enthusiasm for the role of advanced algorithms to improve prediction; just as modern electronic health records (EHRs) pull complex data for clinicians to use in real time, algorithms could pull and process these data in parallel, presenting accurate probability forecasts to clinicians and patients.^[@zoi180067r30]^ However, little evidence suggests that such algorithms can provide meaningful inputs to clinical decision making in cancer or elsewhere.

New chemotherapy is a critical event in the disease trajectory of cancer, and objective predictions of short-term mortality at this time could be useful to physicians and patients in several ways. Accurate forecasts of the risks of mortality and adverse events could inform discussions of risks and benefits of chemotherapy, particularly for patients undergoing palliative chemotherapy, and could help guide important decisions regarding advance care planning and palliative care consultation. In this study, we developed and applied a machine learning algorithm to predict near-term mortality risk in a large cohort of patients with cancer starting new chemotherapy regimens.

Methods {#H1-2-ZOI180067}
=======

Study Population {#H2-1-ZOI180067}
----------------

We obtained EHR data for all patients receiving chemotherapy at the Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC), Boston, Massachusetts, from January 1, 2004, through December 31, 2014. We determined date of death by linking to the Social Security Administration's Death Master File. We classified patients by primary cancer and presence of distant-stage disease, determined using registry data (for patients diagnosed at DF/BWCC) and *International Classification of Diseases, Ninth Revision* (*ICD-9*) codes for metastases (for patients not diagnosed at DF/BWCC or who did not have registry data and to identify progression to distant-stage disease in those previously diagnosed at DF/BWCC).^[@zoi180067r31]^ Although diagnosis codes have limitations for determination of cancer stage, they are generally believed to provide reliable identification of the presence or the absence of distant-stage disease.^[@zoi180067r32]^ Our study followed the transparent reporting of a multivariable prediction model for individual prognosis or diagnosis ([TRIPOD](http://www.equator-network.org/reporting-guidelines/tripod-statement/)) checklist for prediction model development and validation (eMethods in the [Supplement](#note-ZOI180067-1-s){ref-type="supplementary-material"}).The institutional review boards of Dana-Farber Cancer Institute and Partners HealthCare, Boston, approved this study and granted a waiver of informed consent from study participants.

Statistical Analysis {#H2-2-ZOI180067}
--------------------

### Outcomes {#H3-1-ZOI180067}

Data were analyzed from June 1 through August 1, 2017. Our primary outcome was death within 30 days of starting new systemic chemotherapy regimens. Secondary outcomes were 30-day mortality in prespecified subgroups of interest (described later) and overall 180-day mortality. We constructed our data set at the patient--chemotherapy regimen level, such that each regimen was a new observation.

### Model Performance {#H3-2-ZOI180067}

Machine learning models have the potential to overfit or produce overly optimistic estimates of model performance based on spurious correlations in development data. We thus report results only in an independent validation set, which played no role in model development; as such, overfitting would only lead to poorer model performance in the validation set. Specifically, we used data from 2004 through 2011 for model derivation and data from 2012 through 2014 for model validation. Because our data set was constructed at the patient--chemotherapy regimen level, observations describing different chemotherapy regimens in the same patient are not independent. For patients whose observations appeared before and after January 1, 2012, we randomly assigned all observations from a given patient to the derivation or the validation set, so that no patient appeared in both sets.

### Statistical Tests {#H3-3-ZOI180067}

Our primary measure of model performance was the area under the receiver operating characteristic curve (AUC),^[@zoi180067r33]^ which we calculated by comparing the mortality probability estimate from the machine learning model with observed mortality. We calculated 95% CIs of the AUC following the method of DeLong et al.^[@zoi180067r34]^ We report AUC overall and in subgroups of clinical interest, notably age, sex, race/ethnicity, distant-stage disease, individual primary cancers, chemotherapy lines and regimens, and chemotherapy intent (palliative vs curative, identified by the treating physician and recorded as an EHR flag). To benchmark against existing prognostic models, we obtained 1-year mortality estimates from large RCTs of specific chemotherapy regimens and from the SEER program for available subgroups of patients. To give more clinically relevant metrics of predictive accuracy, we also present mortality rates in given deciles of model-predicted risk, typically highest and lowest. When presenting variable summary statistics, we report CIs for means and proportions and the first and third quartiles for medians.

### Predictors {#H3-4-ZOI180067}

To transform raw EHR data into variables usable in a prediction model, we first pulled all data from the 1-year period ending the day before chemotherapy initiation (we did not drop patients based on absence of data during this period). Raw data were aggregated into 23 641 potential predictors in the following categories: demographics, prescribed medications, comorbidities and other grouped *ICD-9* diagnoses, procedures,^[@zoi180067r31]^ use of health care resources, vital signs, laboratory results, and terms derived from physician notes using natural language processing.^[@zoi180067r31]^ For each potential predictor, we created the the statistical summary of related EHR entries for 1 month (recent) and for 2 to 12 months (baseline) before chemotherapy initiation. This strategy is outlined in more detail elsewhere.^[@zoi180067r35]^ We also included a variable indexing how many lines of chemotherapy the patient had in total before the current regimen. No data on the current regimen itself (eg, agent, intent) were used in the predictive model. We dropped variables missing in more than 99% of the derivation sample, leaving 5390 predictors in the model.

### Algorithm {#H3-5-ZOI180067}

We used gradient-boosted trees, a linear combination of decision trees similar to those used to derive many clinical decision rules to handle large sets of correlated predictors (R package: xgboost).^[@zoi180067r36],[@zoi180067r37]^ We used 4-fold cross-validation in the development sample to choose model variables (eg, number of trees, variables per tree). The model was configured to produce individual-level probabilities of 30-day mortality. More details are available in eMethods in the [Supplement](#note-ZOI180067-1-s){ref-type="supplementary-material"}.

### Missing Values {#H3-6-ZOI180067}

Each split of each tree in the model (eg, a split on sex) had a default, which is the value (eg, male or female) that occurred more frequently in the training data. Observations with missing values for a given variable were assigned to the default side of the split. This process was effectively a split-specific, probabilistic imputation function that allowed us to avoid excluding observations that were missing data.

### Model Variance {#H3-7-ZOI180067}

We decomposed model predictions into the linear contributions of individual variables. We calculated the (linear) sum of squares for individual variables included in the machine learning model and interpreted the residual sum of squares as the contribution of nonlinear terms and interactions used by the model. Because our model used more than 5000 predictors, we chose to report on only a small selection, specifically (1) those that most explained model variance and (2) those identified as predictors of mortality in prior studies.^[@zoi180067r29],[@zoi180067r38],[@zoi180067r39]^ Details on our calculation of the model variance explained by individual predictors are in eMethods in the [Supplement](#note-ZOI180067-1-s){ref-type="supplementary-material"}.

Results {#H1-3-ZOI180067}
=======

Study Population {#H2-3-ZOI180067}
----------------

We identified 26 946 patients who initiated 51 774 discrete chemotherapy regimens from 2004 through 2014; 59.4% had distant-stage disease. [Table 1](#zoi180067t1){ref-type="table"} shows patient characteristics at the time of chemotherapy initiation. Mean patient age was 58.7 years (95% CI, 58.5-58.9 years), 61.1% were female (95% CI, 60.4%-61.9%), and 86.9% were white (95% CI, 86.4%-87.4%). The most common chemotherapy regimens (derivation and validation sets) were carboplatin and paclitaxel (n = 4042), gemcitabine hydrochloride (n = 2185), and albumin-bound paclitaxel (n = 1985); 3.3% of chemotherapy regimens in the validation set (n = 523) were chemotherapy regimens that first appeared in 2012 or later and thus did not appear in the derivation set. Experimental agents not approved by the US Food and Drug Administration constituted 2.2% (n = 343) of all chemotherapy regimens in the validation set.

###### Patient Characteristics of Model Derivation and Validation Sets

  Variable                                                                       Set                                         
  ------------------------------------------------------------------------------ --------------------- --------------------- -------------------------------------------------------
  No. of chemotherapy regimens                                                   36 007                15 767                20 240
  Age, mean (95% CI), y                                                          58.7 (58.5 to 58.9)   60.7 (60.5 to 61.0)   −2.1 (−2.4 to −1.7)
  Female, % (95% CI)                                                             61.1 (60.4 to 61.9)   60.7 (59.7 to 61.7)   0.5 (−0.7 to 1.7)
  White, % (95% CI)                                                              86.9 (86.4 to 87.4)   88.3 (87.7 to 89.0)   −1.5 (−2.3 to −0.7)
  Inpatient visit, % (95% CI)                                                    43.9 (43.2 to 44.6)   38.0 (37.0 to 38.9)   6.0 (4.7 to 7.2)
  Gagne score, median (IQR)                                                      2 (1 to 6)            1 (1 to 6)            −1 (0 to 0)[^a^](#zoi180067t1n1){ref-type="table-fn"}
  Cancer type, % (95% CI)                                                                                                    
  Breast                                                                         23.6 (23.0 to 24.3)   21.1 (20.2 to 21.9)   2.5 (1.5 to 3.6)
  Colon and rectum                                                               17.6 (17.1 to 18.2)   19.3 (18.5 to 20.2)   −1.7 (−2.7 to −0.7)
  Lung and bronchus                                                              17.7 (17.2 to 18.3)   18.0 (17.2 to 18.8)   −0.3 (−1.3 to 0.7)
  Hematologic                                                                    7.1 (6.7 to 7.5)      8.4 (7.8 to 8.9)      −1.3 (−2.0 to −0.6)
  Ovary                                                                          6.7 (6.3 to 7.0)      7.7 (7.1 to 8.2)      −1.0 (−1.7 to −0.3)
  Other                                                                          27.8 (27.1 to 28.4)   25.8 (24.9 to 26.7)   2.0 (0.9 to 3.1)
  Chemotherapy beyond first line, % (95% CI)                                     49.0 (48.3 to 49.7)   42.4 (41.4 to 43.4)   6.6 (5.3 to 7.8)
  Intent of chemotherapy, % (95% CI)[^b^](#zoi180067t1n2){ref-type="table-fn"}                                               
  Curative                                                                       15.7 (15.3 to 16.1)   26.8 (26.1 to 27.5)   −11.1 (−11.9 to −10.3)
  Palliative                                                                     33.8 (33.3 to 34.3)   46.6 (45.8 to 47.3)   −12.7 (−13.7 to −11.8)

Abbreviation: IQR, interquartile range.

Calculated by quantile regression.

Intent of chemotherapy does not add up to 100% owing to missing values, resulting in unknown intent.

Model Performance {#H2-4-ZOI180067}
-----------------

Among the 9114 patients in the validation set, overall 30-day mortality was 2.1% (95% CI, 1.9%-2.4%). The most common primary cancers were breast (21.1%; 95% CI, 20.2%-21.9%), colorectal (19.3%; 95% CI, 18.5%-20.2%), and lung (18.0%; 95% CI, 17.2%-18.8%). The model accurately predicted 30-day mortality for all patients, irrespective of chemotherapy intent (AUC, 0.940; 95% CI, 0.930-0.951). In the subset of patients receiving palliative chemotherapy (46.6% of regimens; 95% CI, 45.8%-47.3%), 30-day mortality was 3.1% (95% CI, 2.7%-3.5%). Prognostic estimates are likely to be particularly important for these patients, and the model also performed well for this situation, with an AUC of 0.924 (95% CI, 0.910-0.939). To illustrate the clinical implications of this accuracy, we used model predictions to individually rank patients by 30-day mortality risk, a commonly used way of stratifying risk groups.^[@zoi180067r33]^ Thirty-day mortality in the highest decile of predicted risk for palliative-intent chemotherapy was 22.6% (95% CI, 19.6%-25.6%), whereas in the lowest-risk decile, no patients died.

[Figure 1](#zoi180067f1){ref-type="fig"} shows observed survival during the 180 days after palliative chemotherapy initiation by decile of model predictions (patients were followed up to 180 days). Overall 180-day mortality among all patients was 18.4% (95% CI, 17.8%-19.0%); for those initiating palliative chemotherapy, 180-day mortality was 27.9% (95% CI, 26.9%-28.9%). Model predictions on 30-day mortality were also accurate predictors of 180-day mortality (AUC, 0.827; 95% CI, 0.817-0.838); in the highest-risk decile, 180-day mortality was 74.8% (95% CI, 72.7%-77.0%) vs 0.2% (95% CI, 0.01%-0.4%) in the lowest-risk decile. Predictions were even more accurate for all patients, irrespective of chemotherapy intent (AUC, 0.870; 95% CI, 0.862-0.877); 180-day survival among these patients is shown in the eFigure in the [Supplement](#note-ZOI180067-1-s){ref-type="supplementary-material"}.

![Observed 180-Day Survival From the Initiation of Palliative Chemotherapy\
Data are stratified by decile of model-predicted mortality risk. Decile 1 denotes the highest predicted risk decile; decile 10, the lowest. Overall denotes overall mean survival among all patients, irrespective of model-predicted risk.](jamanetwopen-1-e180926-g001){#zoi180067f1}

[Table 2](#zoi180067t2){ref-type="table"} shows model performance for predicting 30-day mortality in additional patient subgroups of interest. The model performed equally well across many kinds of primary cancers, demographic groups, and chemotherapy regimens. In distant-stage disease (mean 30-day mortality, 2.9%; 95% CI, 2.5%-3.2%), 30-day mortality in the highest-risk decile was 22.7% (95% CI, 19.9%-25.6%) vs 0 in the lowest decile (AUC, 0.924; 95% CI, 0.910-0.939). Predictions were accurate even for experimental clinical trial regimens first used from 2012 to 2014 (AUC, 0.942; 95% CI, 0.882-1.000); the derivation model was not exposed to these novel regimens in the training process.

###### Model Performance in Selected Subgroups

  Subgroup                                                                AUC (95% CI)          No. in Validation Sample   
  ----------------------------------------------------------------------- --------------------- -------------------------- --------
  Intent of chemotherapy                                                                                                   
  Curative                                                                0.981 (0.970-0.992)   0.892 (0.872-0.912)        4220
  Palliative                                                              0.924 (0.910-0.939)   0.827 (0.817-0.838)        7345
  Stage                                                                                                                    
  Distant                                                                 0.938 (0.926-0.951)   0.852 (0.842-0.861)        8531
  Nondistant                                                              0.936 (0.916-0.955)   0.874 (0.862-0.887)        7236
  Cancer                                                                                                                   
  Breast                                                                  0.970 (0.956-0.983)   0.939 (0.928-0.951)        3408
  Colon and rectum                                                        0.924 (0.898-0.949)   0.843 (0.827-0.860)        2868
  Lung and bronchus                                                       0.916 (0.884-0.949)   0.820 (0.803-0.838)        2822
  Ovary                                                                   0.956 (0.922-0.989)   0.895 (0.871-0.918)        1632
  Hematologic                                                             0.943 (0.902-0.983)   0.819 (0.782-0.856)        1435
  Head and neck                                                           0.970 (0.933-1.000)   0.839 (0.798-0.879)        739
  Cervix uteri                                                            0.955 (0.906-1.000)   0.888 (0.847-0.929)        599
  Prostate                                                                0.936 (0.849-1.000)   0.805 (0.751-0.858)        429
  Chemotherapy regimen                                                                                                     
  Carboplatin plus paclitaxel                                             0.940 (0.859-1.000)   0.846 (0.813-0.880)        1297
  FOLFOX                                                                  0.952 (0.923-0.982)   0.863 (0.833-0.893)        719
  Gemcitabine hydrochloride                                               0.865 (0.789-0.942)   0.992 (0.982-1.000)        547
  Pemetrexed plus carboplatin                                             0.960 (0.939-0.981)   0.807 (0.769-0.845)        518
  Paclitaxel                                                              0.989 (0.972-1.000)   0.738 (0.686-0.791)        505
  Novel clinical trial agents[^a^](#zoi180067t2n1){ref-type="table-fn"}   0.942 (0.882-1.000)   0.870 (0.817-0.923)        343
  Line of chemotherapy                                                                                                     
  First                                                                   0.941 (0.925-0.956)   0.865 (0.854-0.875)        9114
  Subsequent                                                              0.938 (0.924-0.952)   0.864 (0.854-0.874)        6653
  Year[^b^](#zoi180067t2n2){ref-type="table-fn"}                                                                           
  2012                                                                    0.951 (0.935-0.966)   0.887 (0.875-0.899)        5169
  2013                                                                    0.935 (0.914-0.955)   0.869 (0.857-0.882)        4863
  2014                                                                    0.928 (0.908-0.947)   0.837 (0.824-0.851)        4915
  Age group, y                                                                                                             
  21-40                                                                   0.963 (0.939-0.988)   0.901 (0.874-0.928)        1057
  41-60                                                                   0.950 (0.935-0.966)   0.893 (0.883-0.903)        6263
  61-80                                                                   0.936 (0.920-0.951)   0.850 (0.839-0.861)        7626
  81-100                                                                  0.876 (0.806-0.947)   0.803 (0.768-0.838)        806
  Sex                                                                                                                      
  Male                                                                    0.927 (0.910-0.944)   0.840 (0.828-0.852)        5799
  Female                                                                  0.948 (0.935-0.962)   0.886 (0.877-0.894)        9968
  Race/ethnicity                                                                                                           
  White                                                                   0.940 (0.929-0.951)   0.870 (0.862-0.877)        13 960
  Nonwhite                                                                0.941 (0.909-0.972)   0.870 (0.850-0.891)        1807
  Insurance                                                                                                                
  Private                                                                 0.949 (0.937-0.962)   0.886 (0.878-0.895)        10 415
  Medicare                                                                0.938 (0.911-0.965)   0.854 (0.837-0.872)        2699
  Medicaid                                                                0.945 (0.914-0.976)   0.824 (0.784-0.865)        611
  Self-pay                                                                0.932 (0.851-1.000)   0.821 (0.753-0.888)        210

Abbreviations: AUC, area under the receiver operating characteristic curve; FOLFOX, leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.

Indicates subgroup of patients receiving new clinical trial regimens first observed during 2012 through 2014 (ie, years of data to which the model was not exposed in the training process).

Observations in the validation set occurring in 2011 (n = 717) were reassigned to 2012 for the purpose of this Table.

A key question is whether model predictions are accurate enough to be useful across a range of primary cancers, stages of disease, or lines of chemotherapy, which constitute scenarios for which prognoses vary widely. [Table 2](#zoi180067t2){ref-type="table"} thus also presents measures of overall predictive accuracy for first-line chemotherapy (AUC for 30-day mortality, 0.941 \[95% CI, 0.925-0.956\]; AUC for 180-day mortality, 0.865 \[95% CI, 0.854-0.875\]) compared with later lines of chemotherapy (AUC for 30-day mortality, 0.938 \[95% CI, 0.924-0.952\]; AUC for 180-day mortality, 0.864 \[95% CI, 0.854-9.874\]). eTable 1 in the [Supplement](#note-ZOI180067-1-s){ref-type="supplementary-material"} presents extended results on model performance for 30- and 180-day mortality across lung, colorectal, breast, and prostate cancers by stage and line of chemotherapy.

Comparisons With Other Prognostic Estimates {#H2-5-ZOI180067}
-------------------------------------------

We compared model performance with 2 external sources of mortality estimates, focusing on patients with distant-stage disease. First, we obtained mortality data from 4 RCTs of treatments for colorectal adenocarcinoma, non--small cell lung adenocarcinoma, small cell lung carcinoma, and squamous cell carcinoma of the head and neck.^[@zoi180067r40],[@zoi180067r41],[@zoi180067r42],[@zoi180067r43]^ [Figure 2](#zoi180067f2){ref-type="fig"}A-D shows observed mortality for patients in our validation sample who started specific chemotherapy regimens for which trial data are available. (We chose to show 1-year mortality because this is the only time window reported consistently in RCTs.) We compared observed mortality with 2 sources of predictions: (1) RCT data (ie, mean 1-year mortality for patients receiving the relevant chemotherapy regimen) and (2) 1-year mortality risk estimates from our model; to generate these, we calculated 1-year mortality in the derivation set for patients in each quintile of model-predicted risk (we could not use raw model predictions because these were designed to predict 30-day mortality). The overall AUC for RCT estimates was 0.555 (95% CI, 0.513-0.598) compared with 0.771 (95% CI, 0.735-0.808) for model-based estimates for these same patients.

![One-Year Mortality After Chemotherapy Initiation\
A-D, Mortality data from 4 randomized clinical trials^[@zoi180067r40],[@zoi180067r41],[@zoi180067r42],[@zoi180067r43]^ compared with the machine learning model predictions for patients in the validity sample. The randomized clinical trials compared bevacizumab and oxaliplatin,^[@zoi180067r40]^ pemetrexed and carboplatin,^[@zoi180067r41]^ etoposide and carboplatin,^[@zoi180067r42]^ and carboplatin and paclitaxel.^[@zoi180067r43]^ E-H, Mortality estimates from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program compared with the machine learning model predictions. The 45° dotted lines denote equivalence of observed and estimated mortality. Orange lines and shaded 95% CIs show observed 1-year mortality against quintiles of model-predicted 30-day mortality risk. Blue lines and shaded 95% CIs show observed 1-year mortality against predictions from 1-year mortality and 95% CI for trial patients taking a given regimen and 1-year mortality estimates from the SEER program, by type, age, sex, and race/ethnicity.](jamanetwopen-1-e180926-g002){#zoi180067f2}

We also compared our model predictions of mortality with age-, sex-, race-, and cancer-specific mortality estimates from SEER, restricted to patients with advanced-stage cancers of the lung and bronchus, colon and rectum, breast, and prostate to maximize comparability in populations. [Figure 2](#zoi180067f2){ref-type="fig"}E-H shows that our model predictions (AUC, 0.810; 95% CI, 0.799-0.822) outperformed SEER estimates (AUC, 0.600; 95% CI, 0.585-0.615) for 1-year mortality. Further details on construction of RCT and SEER estimates are available in the eMethods and eTable 2 in the [Supplement](#note-ZOI180067-1-s){ref-type="supplementary-material"}, and more detailed comparisons for subgroups are available in eTable 3 in the [Supplement](#note-ZOI180067-1-s){ref-type="supplementary-material"}.

Key Predictors {#H2-6-ZOI180067}
--------------

[Table 3](#zoi180067t3){ref-type="table"} shows the distribution of key predictor variables used in the prediction model across risk deciles, as well as the proportion of model variance explained linearly by each variable. In general, key predictors of mortality identified in the literature were markedly different in the highest vs lowest model-predicted risk deciles; these predictors included summed comorbidity score,^[@zoi180067r39]^ age,^[@zoi180067r38]^ failure to thrive, heart rate, and certain laboratory data (eg, C-reactive protein level, white blood cell count, and alkaline phosphatase level).^[@zoi180067r29]^ Of importance, no single variable explained more than 2% of model predictions in linear fashion. Most of the variation in the predictions (86.4%) was not a linear function of any single predictor, indicating that the tree-based model relied heavily on complex nonlinear functional forms and interactions among variables.

###### Selected Predictors by Risk Decile and Model Variance Explained

  Predictor                                                          Risk Decile   Model Variance Explained, %           
  ------------------------------------------------------------------ ------------- ----------------------------- ------- ------
  Cancer of the brain and with other nervous system areas, %         6.7           1.6                           0.0     1.94
  Demographics                                                                                                           
  Mean age, y                                                        62.3          62.1                          51.9    1.30
  Female, %                                                          56.4          60.9                          86.9    1.17
  Black, %                                                           3.8           3.6                           3.4     0.07
  Mean comorbidity score[^a^](#zoi180067t3n1){ref-type="table-fn"}   5.14          3.44                          2.01    0.03
  Prior diagnoses, %                                                                                                     
  Ascites                                                            0.31          0.07                          0.01    0.39
  Mouth disorder                                                     0.02          0.01                          0.01    0.25
  Nausea and vomiting                                                0.23          0.09                          0.01    0.18
  Lower respiratory tract disorders                                  2.10          1.36                          0.16    0.03
  Secondary malignant neoplasm                                       5.57          1.69                          0.36    0.01
  Failure to thrive                                                  0.05          0.01                          0.00    0.01
  Nutritional disorders                                              2.53          1.63                          0.54    0.00
  Malaise and fatigue                                                0.22          0.08                          0.02    0.00
  Medications, %                                                                                                         
  Corticosteroids                                                    0.53          0.00                          0.00    0.15
  Opioids                                                            0.29          0.00                          0.00    0.05
  Anxiolytics                                                        0.60          0.24                          0.18    0.02
  Cathartics                                                         0.54          0.00                          0.00    0.00
  Vital signs[^b^](#zoi180067t3n2){ref-type="table-fn"}                                                                  
  Maximum pulse, bpm (baseline)                                      106.1         95.7                          87.1    0.37
  Maximum weight, kg (baseline)                                      79.5          80.2                          76.8    0.11
  Weight, SD, kg (baseline)                                          3.1           2.1                           1.3     0.06
  Minimum pulse, bpm (recent)                                        83.4          72.8                          63.0    0.01
  Weight change, kg[^c^](#zoi180067t3n3){ref-type="table-fn"}        −3.1          −1.0                          0.1     0.00
  Laboratory findings[^d^](#zoi180067t3n4){ref-type="table-fn"}                                                          
  Maximum C-reactive protein level, mg/L                             93.9          65.6                          2.2     0.19
  Maximum ALT level, U/L                                             75.9          57.3                          24.3    0.07
  Maximum AST level, U/L                                             73.7          54.2                          23.8    0.09
  Maximum white blood cell count, ×10^3^/μL                          13.9          12.4                          9.8     0.03
  Maximum alkaline phosphatase, IU/L                                 199.5         128.7                         76.5    0.02
  Mean lymphocyte count, ×10^3^/μL                                   1.0           1.3                           1.8     0.00
  Mean platelet count, ×10^3^/μL                                     251.8         241.4                         265.1   0.00
  Ejection fraction, %                                               54.4          48.0                          51.9    0.01
  Total linear terms                                                 NA            NA                            NA      13.6
  Total nonlinear terms and interactions                             NA            NA                            NA      86.4

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; NA, not applicable.

SI conversion factors: To convert ALT, AST, and alkaline phosphatase to microkatals per liter, multiply by 0.0167; C-reactive protein to nanomoles per liter, multiply by 9.524; and white blood cell count, lymphocyte count, and platelet count to ×10^9^ per liter, multiply by 1.

Scores range from 0 to 26, with higher scores indicating more comorbidites.

Baseline and recent denote the value of the predictor (minimum, maximum, or SD, as noted) during the 2 to 12 months and the 1 month before chemotherapy initiation, respectively.

Indicates the change from the mean value during the 2 to 12 months before to the mean value during the 1 month before chemotherapy initiation.

Indicates the value of the predictor (minimum or maximum as noted) during the 12 months before chemotherapy initiation.

Discussion {#H1-4-ZOI180067}
==========

A machine learning model based on single-center EHR data accurately estimated individual mortality risk in a cohort of patients with cancer at the time of chemotherapy initiation. The model performed well across a range of cancer types, race, sex, and other demographic variables. Mortality estimates were accurate for chemotherapy regimens with palliative and curative intent, for patients with early- and distant-stage cancer, and for patients treated with clinical trial regimens introduced in years after the model was trained. Our model outperformed estimates from RCTs and SEER data, both of which are routinely used by clinicians for quantitative risk predictions.

This model was able to predict mortality with considerable accuracy despite lacking genetic sequencing data, cancer-specific biomarkers, or any detailed information about cancers beyond EHR data. This accuracy underscores the fact that common clinical data elements contained within an EHR (eg, symptoms, comorbidities, prescribed medications, and diagnostic tests) contain surprising amounts of signal for predicting key outcomes in patients with cancer.

One clinically useful advantage of our algorithm is that it would not require manual input from clinicians. Current validated prognostic algorithms require considerable, often difficult input on the part of clinicians. For example, the palliative prognostic score relies on 6 weighted variables; some of these data elements, such as Karnofsky performance status, are not routinely available in the EHR and thus require manual input and calculation.^[@zoi180067r21]^

In contrast, our prognostic algorithm could pull directly from the EHR without manual input. Most inputs to our model are standard data elements in structured format in EHRs, including *ICD-9* and procedure codes and medications. Although our algorithm was developed using a single institution's data, its inputs are available nearly everywhere with an EHR. In addition, no special infrastructure is required to pull these data from an institution's data warehouse; in the same way that today's EHR systems pull a rich set of data from a database to present it to clinicians, an algorithm could pull and process the same data in real time using the processing power on a desktop computer. Although machine learning algorithms require significant computing infrastructure to construct, once derived, they can be applied using minimal computing power already available in any hospital computers running an EHR or even on a smartphone. This application facilitates potential integration into existing clinical systems. Thus, we would not anticipate major technical barriers to implementing this or similar algorithms in any organization's clinical data to independently validate predictive power from a sample. To this end, code for our algorithm is publicly available (eResults in the [Supplement](#note-ZOI180067-1-s){ref-type="supplementary-material"} and <http://labsysmed.org/wp-content/uploads/2017/02/ChemoMortalityAnalysis.rtf>).

Algorithmic predictions such as ours could be useful at several points along the care continuum. They could provide accurate predictions of mortality risk to a clinician or foster shared decision making between the patient and clinician. Short-term estimates of mortality could help clinicians identify patients unlikely to benefit from chemotherapy beyond 30 days and those who may benefit from early palliative care referral, advance care planning, and prompting to get financial and family affairs in order. For patients receiving systemic chemotherapy, an estimate of 30-day mortality risk may be a useful quality indicator of avoidable treatment-associated harm.^[@zoi180067r44]^

Limitations {#H2-7-ZOI180067}
-----------

This study has several limitations. Our model was built on data from patients treated with chemotherapy and is thus unlikely to be accurate for untreated patients. Second, our treated sample reflects the particular decisions around chemotherapy made by physicians and patients in our training data set. Patients who were eligible for chemotherapy but for some reason did not start it were not included, which could have biased the sample. However, it is likely that the direction of this bias is that prevailing treatment decisions are generally aggressive. In our sample, 62.4% of patients with distant-stage disease received chemotherapy, suggesting that physician recommendations and patient acceptance of those decisions generally lead to initiation of treatment. This finding fits with a large body of evidence suggesting that physicians in a wide range of settings overestimate survival and overuse chemotherapy. Thus, to the extent that our data set has bias, it leads to the inclusion---not exclusion---of patients who otherwise might not have received chemotherapy. As a result, we believe that this bias did not substantially distort validity. If such an algorithm were deployed in a real-world setting, periodic retraining of the model (eg, each year or quarter) would ensure that model predictions reflected contemporaneous chemotherapy decision making. This process would address changing selection into treatment over time and update the model to reflect broader changes in patient populations and chemotherapy technology.

Several significant differences between the 2004-2011 derivation set and the 2012-2014 validation set include age at initiation, race, primary cancer, and prior chemotherapy beyond the first-line treatment. Such differences between derivation and validation sets are expected and intentional: a validation set drawn from later years of data was chosen to reflect the constant evolution of cancer epidemiology and treatment. This process made the prediction task more difficult because algorithms trained on past data cannot always perform well in the future.^[@zoi180067r45]^ However, changes in referral patterns, chemotherapy, and diagnosis patterns are just some of the difficulties associated with algorithms in evolving real-world settings. We are reassured that performance was good despite these and other secular trends.

Although we quantified predictive accuracy in an independent, recent validation set, the only way to truly validate such a model is prospectively. A model trained on pre-2012 data may lose accuracy as novel tumor diagnostics and therapies arise, although the accuracy of predictions for patients starting novel chemotherapies was encouraging in this regard. In addition, this study included data from a single institution. Further validation is required using cohorts from different institutions. Electronic health record data contain a multitude of biases introduced by physician behavior, institutional idiosyncrasies, and software platforms, among other limitations. These limitations can significantly affect the adaptability and relevance of our prediction model to different care settings.

Conclusions {#H1-5-ZOI180067}
===========

Our machine learning model accurately predicted mortality risk in patients at the time of chemotherapy initiation. Although we are optimistic that accurate prognostic tools such as this could help to promote value-driven oncology care, the ideal next step would be an RCT of algorithmic estimates at the point of care. To be useful, predictive models must improve decision making in the real world. Thus, rigorous evaluation of predictions' influence on outcomes is the criterion standard test but one that is often neglected in the literature, which focuses primarily on measuring predictive accuracy rather than real outcomes.
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